Nations with high smoking rate have low SARS-CoV-2 infection and low COVID-19 mortality rate

Main Article Content

Giovanni Landoni
Alberto Zangrillo
Carolina Soledad Romero García
Carolina Faustini
Martina Di Piazza
Francesca Conte
Simone Gattarello
Artem Kuzovlev
Valery Likhvantsev
Riccardo Puglisi

Keywords

COVID-19; tobacco; smoking; critical care; intensive care, mortality

Abstract

Background and aim of the work


The effect of tobacco smoking on COVID-19 disease is debated with common sense and experts suggesting a deleterious effect and manuscripts worldwide reporting a low prevalence of active tobacco smokers among intensive care unit patients.


Methods


We categorized countries worldwide into three groups with <25%; 25-45%; >45% of active male smokers with data expressed as median and interquartile range [IQR] and extracted data on SARS-CoV-2 infections and COVID-19 deaths per million inhabitants. We also applied multivariate regression techniques to adjust for several epidemiological factors.


Results


COVID-19 mortality was 13 (5-24) per million inhabitants in countries with male smokers >45% and 33 (4-133) in countries where male smokers were <25%. SARS-CoV-2 infection rates were 436 (217-954) and 1139 (302-4084) with data confirmed when dividing data for each continent and when controlling for confounding factors.


Conclusions


We found a counterintuitive low COVID-19 mortality and SARS-CoV-2 infection in countries with high prevalence of male smokers at the global level and within each continent, suggesting that active smoking habit is protective. Further research should urgently investigate which is the possible mechanism of action.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 3 |

References

[1]. Worldometer. COVID‐19 Coronavirus Pandemic. Available from: https://www.worldometers.info/coronavirus/. [Last accessed on August 31st 2020]
[2]. Ciceri F, Castagna A, Rovere-Querini P, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol 2020; [Epub ahead of print] https://doi.org/10.1016/j.clim.2020.108509
[3]. Landoni G, Moro M, Belletti A et al. Recent exposure to smoking and COVID-19. Crit Care Resusc 2020; [Epub ahead of print]
[4]. World Health Organization. Prevalence of tobacco smoking. Available from: https://www.who.int/gho/tobacco/use/en/. [Last accessed on August 28th 2020]
[5]. Landoni G, Losi D, Fresilli S, et al. Is time our ultimate ally in defying the pandemic? Pathogens and Global Health 2020, DOI: 10.1080/20477724.2020.1785199
[6]. United Nations, Department of Economic and Social Affairs. World Population Prospects. Available from:
https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/CSV_FILES/WPP2019_TotalPopulationBySex.csv [Last accessed on August 30th 2020]
[7]. World Bank, World Development Indicators. Available from:
https://databank.worldbank.org/reports.aspx?source=2&series=NY.GDP.PCAP.PP.CD and
https://databank.worldbank.org/reports.aspx?source=2&series=SP.POP.65UP.TO.ZS
[Last accessed on August 30th 2020]
[8]. Garcia Calzado MC, Garcia Rojas JF, Mangas Rojas A, et al. Tobacco and arterial pressure (II.). The acute effects on the angiotensin-converting enzyme. An Med Interna 1990; 7:392-395 [Article in Spanish]
[9]. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res 2020; 43:648-654